234 related articles for article (PubMed ID: 35422096)
21. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Benjamin R; Graham C; Yallop D; Jozwik A; Mirci-Danicar OC; Lucchini G; Pinner D; Jain N; Kantarjian H; Boissel N; Maus MV; Frigault MJ; Baruchel A; Mohty M; Gianella-Borradori A; Binlich F; Balandraud S; Vitry F; Thomas E; Philippe A; Fouliard S; Dupouy S; Marchiq I; Almena-Carrasco M; Ferry N; Arnould S; Konto C; Veys P; Qasim W;
Lancet; 2020 Dec; 396(10266):1885-1894. PubMed ID: 33308471
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan.
Wakase S; Teshima T; Zhang J; Ma Q; Watanabe Y; Yang H; Qi CZ; Chai X; Xie Y; Wu EQ; Igarashi A
Transplant Cell Ther; 2021 Mar; 27(3):241.e1-241.e11. PubMed ID: 33781519
[TBL] [Abstract][Full Text] [Related]
23. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á; Alonso-Saladrigues A; Herrero B; Caballero-Velázquez T; Galán-Gómez V; Panesso M; Torrebadell M; Delgado-Serrano J; Pérez de Soto C; Faura A; González-Martínez B; Castillo-Robleda A; Diaz-de-Heredia C; Pérez-Martínez A; Pérez-Hurtado JM; Rives S; Pérez-Simón JA
Front Immunol; 2023; 14():1280580. PubMed ID: 38292483
[TBL] [Abstract][Full Text] [Related]
24. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
[TBL] [Abstract][Full Text] [Related]
25. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Pasquini MC; Hu ZH; Curran K; Laetsch T; Locke F; Rouce R; Pulsipher MA; Phillips CL; Keating A; Frigault MJ; Salzberg D; Jaglowski S; Sasine JP; Rosenthal J; Ghosh M; Landsburg D; Margossian S; Martin PL; Kamdar MK; Hematti P; Nikiforow S; Turtle C; Perales MA; Steinert P; Horowitz MM; Moskop A; Pacaud L; Yi L; Chawla R; Bleickardt E; Grupp S
Blood Adv; 2020 Nov; 4(21):5414-5424. PubMed ID: 33147337
[TBL] [Abstract][Full Text] [Related]
26. [CAR-T therapy for pediatric acute lymphoblastic leukemia].
Sakaguchi H
Rinsho Ketsueki; 2023; 64(11):1440-1446. PubMed ID: 38072432
[TBL] [Abstract][Full Text] [Related]
27. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
28. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Moskop A; Pommert L; Baggott C; Prabhu S; Pacenta HL; Phillips CL; Rossoff J; Stefanski HE; Talano JA; Margossian SP; Verneris MR; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston ML; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Guest EM; Breese EH; Schultz LM
Blood Adv; 2022 Jul; 6(14):4251-4255. PubMed ID: 35580324
[TBL] [Abstract][Full Text] [Related]
29. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Shah BD; Bishop MR; Oluwole OO; Logan AC; Baer MR; Donnellan WB; O'Dwyer KM; Holmes H; Arellano ML; Ghobadi A; Pagel JM; Lin Y; Cassaday RD; Park JH; Abedi M; Castro JE; DeAngelo DJ; Malone AK; Mawad R; Schiller GJ; Rossi JM; Bot A; Shen T; Goyal L; Jain RK; Vezan R; Wierda WG
Blood; 2021 Jul; 138(1):11-22. PubMed ID: 33827116
[TBL] [Abstract][Full Text] [Related]
30. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
31. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
Zhang X; Yang J; Li J; Qiu L; Zhang J; Lu Y; Zhao YL; Jin D; Li J; Lu P
Am J Hematol; 2023 Dec; 98(12):1898-1908. PubMed ID: 37740926
[TBL] [Abstract][Full Text] [Related]
32. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.
Cope S; Ayers D; Zhang J; Batt K; Jansen JP
BMC Med Res Methodol; 2019 Sep; 19(1):182. PubMed ID: 31477025
[TBL] [Abstract][Full Text] [Related]
33. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
O'Brien MM; Ji L; Shah NN; Rheingold SR; Bhojwani D; Yuan CM; Xu X; Yi JS; Harris AC; Brown PA; Borowitz MJ; Militano O; Kairalla J; Devidas M; Raetz EA; Gore L; Loh ML
J Clin Oncol; 2022 Mar; 40(9):956-967. PubMed ID: 35007127
[TBL] [Abstract][Full Text] [Related]
34. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
[TBL] [Abstract][Full Text] [Related]
35. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
Schultz LM; Eaton A; Baggott C; Rossoff J; Prabhu S; Keating AK; Krupski C; Pacenta H; Philips CL; Talano JA; Moskop A; Baumeister SHC; Myers GD; Karras NA; Brown PA; Qayed M; Hermiston M; Satwani P; Wilcox R; Rabik CA; Fabrizio VA; Chinnabhandar V; Kunicki M; Mavroukakis S; Egeler E; Li Y; Mackall CL; Curran KJ; Verneris MR; Laetsch TW; Stefanski H
J Clin Oncol; 2023 Jan; 41(2):354-363. PubMed ID: 36108252
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
Furzer J; Gupta S; Nathan PC; Schechter T; Pole JD; Krueger J; Pechlivanoglou P
JAMA Oncol; 2020 Mar; 6(3):393-401. PubMed ID: 31971547
[TBL] [Abstract][Full Text] [Related]
37. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
Halford Z; Anderson MK; Bennett LL; Moody J
Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
[TBL] [Abstract][Full Text] [Related]
38. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
Leahy AB; Elgarten CW; Grupp SA; Maude SL; Teachey DT
Expert Rev Anticancer Ther; 2018 Oct; 18(10):959-971. PubMed ID: 30111196
[TBL] [Abstract][Full Text] [Related]
39. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
[TBL] [Abstract][Full Text] [Related]
40. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
